<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03053076</url>
  </required_header>
  <id_info>
    <org_study_id>GuangdongWCH</org_study_id>
    <nct_id>NCT03053076</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Autologous Umbilical Cord Blood Mononuclear Cells Transfusion in Neonates</brief_title>
  <official_title>Safety and Efficacy of Autologous Umbilical Cord Blood Mononuclear Cells Transfusion in Neonates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Women and Children Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Women and Children Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the safety and efficacy of Autologous Umbilical Cord Blood Mononuclear Cells
      transfusion on clinical outcome in preterm infants
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 clinical trial that constitutes two time points cohorts with 100
      participants per cohort who will receive intravenous doses of Autologous Umbilical Cord Blood
      Mononuclear Cells --25 million cells/kg, 48 hours after birth. And the placebo will be 0.9%
      sodium chloride.The investigator will proceed the groups during the same period.

        1. Demographic Data and Baseline Characteristics of the Studied Groups were collected:

             -  Gestational age (weeks)

             -  Birth weight (g)

             -  gender

             -  Cesarean section delivery

             -  Antenatal steroids

             -  Prolonged rupture of membrane

             -  Multiple pregnancies

             -  APGAR score at 5 minutes

             -  Thrombocytopenia before intervention

             -  CRP before intervention (mg/L)

             -  TNF-α(tumor necrosis factor α ) before intervention (pg/mL)

        2. Assessment of clinical condition in the course by measurement of arterial blood
           pressure, heart and respiratory rates and skin temperature was recorded continuously

        3. Autologous cord blood mononuclear cells doses is 25 million cells/kg ，the infusion speed
           is 4ml/kg/h， 8-12h，and with same volume of 0.9% sodium chloride as placebo.

        4. The following are monitored at 3、7、14、21 days after birth:

             -  mortality, incidence of sepsis, neonatal respiratory distress syndrome (NRDS),
                bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP), necrotising
                enterocolitis (NEC), intraventricular haemorrhage (IVH), Hypoxic Ischemic
                Encephalopathy (HIE), anaemia, thrombocytopenia, neutrophil,TBNK cells subgroup,
                before hospital discharge.

        5. Long-term follow up: in 1m, 3m, 6m,1y: neurodevelopment [Bayley Scales of Infant],
           asthma, anemia and physique growth.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2017</start_date>
  <completion_date type="Anticipated">May 15, 2017</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients who died</measure>
    <time_frame>up tp 21 days after birth</time_frame>
    <description>mortality rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of patients with neurodevelopmental disorder assessed by Bayley Score</measure>
    <time_frame>up to 1 month, 3 months, 6 months and 1 year</time_frame>
    <description>Long term follow up: in 1 month, 3 months, 6 months, and 1 year: neuro-development</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Safety Issues</condition>
  <condition>Effect of Drugs</condition>
  <condition>Neonatal Death</condition>
  <arm_group>
    <arm_group_label>Placebo1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chloride infusion 48 hours after birth ,the infusion speed is 4ml/kg/h， 8-12h，</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBMNC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous Umbilical Cord Blood Mononuclear Cells Therapy 48 hours after birth ,dose is 25 million cells/kg ，the infusion speed is 4ml/kg/h， 8-12h，</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous Umbilical Cord Blood Mononuclear Cells Therapy</intervention_name>
    <description>Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for safety and effect evaluation</description>
    <arm_group_label>CBMNC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% Sodium Chloride</intervention_name>
    <description>0.9% Sodium Chloride in control group</description>
    <arm_group_label>Placebo1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Twenty-eight weeks to thirty-seven weeks

        Exclusion Criteria:

          -  Preterm infants with major congenital malformations, chromosomal anomalies, inborn
             errors of metabolism and clinical or laboratory evidence of a congenital infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>28 Weeks</minimum_age>
    <maximum_age>37 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Yang, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Women and Children Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>zhuxiao Ren, MD</last_name>
    <phone>+8613538984634</phone>
    <phone_ext>+86</phone_ext>
    <email>renzhx1990@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jie Yang</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>511442</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Yang, PHD</last_name>
      <phone>39151777</phone>
      <phone_ext>020</phone_ext>
      <email>jasjie_yang@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013 Jul 25;122(4):491-8. doi: 10.1182/blood-2013-02-453175. Epub 2013 May 14. Review.</citation>
    <PMID>23673863</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2017</study_first_submitted>
  <study_first_submitted_qc>February 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2017</study_first_posted>
  <last_update_submitted>April 7, 2017</last_update_submitted>
  <last_update_submitted_qc>April 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangdong Women and Children Hospital</investigator_affiliation>
    <investigator_full_name>yangjie</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>cord blood mononuclear cells</keyword>
  <keyword>safety</keyword>
  <keyword>effect</keyword>
  <keyword>neonates</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Perinatal Death</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

